Park Avenue Securities LLC Checkpoint Therapeutics, Inc. Transaction History

Park Avenue Securities LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$0.97 - $1.77 $97,000 - $177,000	-100,000 Reduced 47.58%	110,176 $113,000
Q1 2022 Apr 29, 2022	BUY	$1.53 - $3.25 $238,947 - $507,568	156,175 Added 289.21%	210,176 $372,000
Q1 2021 Apr 28, 2021	BUY	$2.6 - $4.16 $457 - $732	176 Added 0.33%	54,001 $170,000
Q2 2020 Jul 30, 2020	BUY	$1.19 - $2.27 $64,051 - $122,182	53,825 New	53,825 $107,000
Q1 2020 Apr 28, 2020	SELL	$1.11 - $2.43 $59,745 - $130,794	-53,825 Closed	0 $0
Q3 2019 Oct 18, 2019	BUY	$2.15 - $3.36 $115,723 - $180,852	53,825 New	53,825 $134,000
Q2 2019 Jul 26, 2019	SELL	$2.75 - $5.0 $183,130 - $332,965	-66,593 Closed	0 $0
Q1 2019 May 02, 2019	BUY	$2.01 - $4.01 $133,851 - $267,037	66,593 New	66,593 $199,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $245M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Park Avenue Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Park Avenue Securities LLC with notifications on news.